|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:approvalYear
|
1989
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N05AH02
|
|
gptkbp:brand
|
gptkb:Denzapine
gptkb:FazaClo
gptkb:Versacloz
gptkb:Zaponex
gptkb:Clozaril
|
|
gptkbp:CASNumber
|
gptkb:5786-21-0
|
|
gptkbp:chemicalClass
|
dibenzodiazepine
|
|
gptkbp:contraindication
|
paralytic ileus
history of agranulocytosis
uncontrolled epilepsy
|
|
gptkbp:countryOfOrigin
|
gptkb:Switzerland
|
|
gptkbp:developedBy
|
gptkb:Sandoz
|
|
gptkbp:discoveredBy
|
gptkb:Wander_AG
|
|
gptkbp:eliminationHalfLife
|
8-12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1960
|
|
gptkbp:hasMolecularFormula
|
C18H19ClN4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
clozapine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1972
|
|
gptkbp:mechanismOfAction
|
antagonist of dopamine D2 receptors
antagonist of serotonin 5-HT2A receptors
antagonist of adrenergic, histaminergic, and cholinergic receptors
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitoringRequirement
|
regular blood tests for white blood cell count
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:PubChem_CID
|
gptkb:DB00363
2818
|
|
gptkbp:riskManagement
|
gptkb:REMS_program_in_the_US
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
weight gain
seizures
myocarditis
sedation
tachycardia
agranulocytosis
hypersalivation
|
|
gptkbp:synonym
|
8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine
|
|
gptkbp:UNII
|
J60AR2IKIC
|
|
gptkbp:usedFor
|
gptkb:schizoaffective_disorder
treatment-resistant schizophrenia
reducing risk of recurrent suicidal behavior in schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:CYP1A2
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|